NCT07086040Not yet recruiting
Effects of RAS in SZ
Effects of Rhythmic Auditory Stimulation Therapy on Upper-Limb Movements, Function, and Quality of Life in Patients With Schizophrenia: Randomized Controlled Trials
Source: ClinicalTrials.gov · Last updated 25 Jul 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The two main groups of medicated patients with schizophrenia (SZ) are those receiving second-generation antipsychotics and those receiving first-generation antipsychotics. The purpose of this research project is to target each patient group to examine effects of rhythmic auditory stimulation (RAS) on upper-limb movements in medicated SZ patients in a 6-month follow-up period. The main questions of this project are: 1. Does RAS reduce severity of upper-limb bradykinesia (slow movements) and dyskinesia (repetitive and involuntary movements) after intervention, at 3-month follow-up and 6-month follow-up in SZ patients receiving second-generation antipsychotics? and 2. Does RAS reduce severity of upper-limb bradykinesia and dyskinesia after intervention, at 3-month follow-up and 6-month follow-up in SZ patients receiving first-generation antipsychotics? Researchers will compare upper-limb movement training with the aid of RAS to upper-limb movement training without the aid of RAS to see if RAS works to improve upper-limb movements in SZ patients. Participants will: 1. Undergo an interview and movement tests and fill out questionnaires before and after the movement training program and at 3-month follow-up and 6-month follow-up; and 2. Receive movement training for 40 minutes per session for a total of 21 sessions.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 140 (estimated)
- First submitted
- 18 Jul 2025
- Start date
- 1 Aug 2025
- Primary completion date
- 31 Jul 2028
- Lead sponsor
- Shu-Mei Wang
- Diseases
- Schizophrenia
- NCT number
- NCT07086040
What you commit to
- Study type: Interventional
- Planned participants: 140
- From 1 Aug 2025 to the primary completion date, 31 Jul 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Substance abuse or drug abuse
- Substance abuse or drug abuse
- Taking psychotropic medications
Other illness
- Neurological diseases or medical conditions that affect upper-limb movements and hearing
- Other psychiatric diagnoses in addition to a diagnosis of schizophrenia or schizoaffective disorder
- \[For healthy participants\]
- Neurological diseases or medical conditions that affect upper-limb movements and hearing
- Psychiatric diagnoses
- Presence of first-degree relatives or siblings with diagnoses of psychiatric diseases.
Who the study is looking for
- A diagnosis of schizophrenia or schizoaffective disorder
- Between 18 to 60 years old
- Keeping the same antipsychotics and the same dosage at least 4 weeks right before joining the study
- A Edinburgh Handedness Inventory score of \> 60
- A Montreal Cognitive Assessment score of ≥ 24
- Between 18 to 60 years old
- A Edinburgh Handedness Inventory score of \> 60
- A Montreal Cognitive Assessment score of ≥ 24
Criteria the registry did not label
- \[For SZ patients\]
Age in the registry: 18 years to 60 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| National Taipei University of Nursing and Health Sciences Coordinator of this site? Confirm its status | Taipei | Taiwan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.